Glaukos, iVeena enter licensing agreement for keratoconus treatment
Click Here to Manage Email Alerts
Glaukos and iVeena Delivery Systems have entered into a strategic licensing agreement that grants Glaukos an exclusive global license to develop and commercialize IVMED-80 for the treatment of keratoconus, according to a press release.
Glaukos paid iVeena $10 million upfront and will assume all costs associated with development and regulatory activities of IVMED-80, a topical eye drop with orphan drug designation that treats keratoconus by upregulating lysyl oxidase and inducing pharmacologic corneal cross-linking to strengthen the cornea.
The deal also includes potential development and sales milestone payments to iVeena, as well as royalties on sales.
“This deal validates the technology we have developed at iVeena to induce corneal cross-linking pharmacologically via eye drops. Glaukos is a strong partner to complete development of this product where, if approved, patients will have an additional keratoconus treatment option,” Jerry Simmons, CEO of iVeena, said in the release.
Read more about
Click Here to Manage Email Alerts